LivingGLP1
crossover randomized trial

S002999

Overweight or obesity without diabetes (adults)Metabolic dysfunction associated steatotic liver disease or steatohepatitisS002999

Design

Randomized
16
Start year
2020
Treatment
32 weeks, follow-up 32 weeks
Countries
Czech Republic
Sponsor
(non industry)
Eligibility
men aged 18 to 70; BMI above 30; waist above 102 cm; no diabetes; hepatic fat above 4 percent

Conduct and analysis

Blinding
open label
Sequence generation
not reported
Allocation concealment
not reported
Outcome adjudication
not reported
Primary estimand
not stated
Analysis population
Missing data

Arms

ArmTreatmentBackgroundRandomizedAnalyzedCompleted treatment
A1Lifestyle intervention (randomized arm)
Dietary intervention period
lifestyle: standard16
A2Semaglutide 1.0 mg subcutaneous once weekly
Semaglutide period (with continued diet)
dietary advice continued; lifestyle: standard16

Baseline characteristics

As printed in the trial reports or registry, per arm or for the whole trial.
CharacteristicStatisticLifestyle intervention (randomized arm)
A1
Semaglutide 1.0 mg subcutaneous once weekly
A2
Whole trial
ALL
agemean (years)47.0
agesd (years)12.4
bmimean (kg/m2)36.2
bmisd (kg/m2)3.8
other hepatic fat contentmean (percent)13.3
other hepatic fat contentsd (percent)8.5
other malen16
waistmean (cm)120
waistsd (cm)10
weightmean (kg)120.3
weightsd (kg)12.0

Results

1 adjudicated result lines, grouped by outcome. Open an outcome to see its values.
Percent body weight change (1 lines; O10)
WeekArmStatisticEstimateSE or SD95% CIEvents / NDetail
16A2percent change-5 percent16not stated; other; R0012572:Abstract